Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BTX161 is a Thalidomide analogue. BTX161 is a potent CKIα degrader. In human AML cells, BTX161 mediates the CKIα degradation better than Lenalidomide as well as activates DNA damage response (DDR) and p53, and also stabilizes the p53 antagonist MDM2[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,140.00 | |
50 mg | 6-8 weeks | $ 1,490.00 | |
100 mg | 6-8 weeks | $ 2,360.00 |
Description | BTX161 is a Thalidomide analogue. BTX161 is a potent CKIα degrader. In human AML cells, BTX161 mediates the CKIα degradation better than Lenalidomide as well as activates DNA damage response (DDR) and p53, and also stabilizes the p53 antagonist MDM2[1]. |
In vitro | BTX161 (25 μM; 4 hours; MV4-11 cells) enhances the expression of Wnt targets such as MYC without altering MDM2 mRNA levels [1]. At a concentration of 10 μM over 6 hours in MV4-11 cells, BTX161 independently increases p53 and MDM2 protein levels. When combined with THZ1, and especially with both THZ1 and CDK9, it further elevates p53 expression and maximizes caspase 3 activation [1]. |
Molecular Weight | 272.3 |
Formula | C15H16N2O3 |
CAS No. | 2052301-24-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BTX161 2052301-24-1 inhibitor inhibit